A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections
Crossref DOI link: https://doi.org/10.1186/s12879-015-0759-5
Published Online: 2015-02-25
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Vickers, Richard
Robinson, Neil
Best, Emma
Echols, Roger
Tillotson, Glenn
Wilcox, Mark
License valid from 2015-02-25
Article History
Received: 31 March 2014
Accepted: 15 January 2015
First Online: 25 February 2015